Topic: renal cell carcinoma
The approval of Bavencio plus Inlyta in first-line kidney cancer puts Pfizer and Merck KGaA in a three-way battle for market share.
A federal jury ruled Aveo's ex-CFO David Johnston made untrue statements about tivozanib and that he made money as a result.
Pfizer has been looking to expand Inlyta's use to kidney cancer patients at a high risk of disease recurrence after surgery—but it's fallen short.
Exelixis shares soared Tuesday after its kidney cancer drug won a broader FDA approval expected to push it past $1 billion in peak sales.
A one-two punch with Bristol-Myers' Opdivo and Yervoy cut the risk of death by 37% for kidney cancer patients with a poor prognosis.
Avastin has been the gift that just keeps on giving for Roche. The VEGF-targeting antibody claimed its first approval in colorectal cancer in 2004 and has steadily added new indications since then, most recently picking up a European approval for use alongside Tarceva for patients with EGFR-positive non-small cell lung cancer.
Bristol-Myers Squibb partner Ono Pharmaceutical bagged a third approval in Japan for immuno-oncology drug Opdivo, its most important new product.
Eisai has won a regulatory nod on an additional indication for the combo therapy of Lenvima and Novartis’ cancer drug Afinitor to treat advanced renal cell carcinoma.